Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2009;105:827-829
doi: 10.1161/CIRCRESAHA.109.208595
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mallat, Z.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mallat, Z.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Pathophysiology
Right arrow Other hypertension
Right arrow Genetically altered mice
Right arrow Genetics of cardiovascular disease
Right arrow Mechanism of atherosclerosis/growth factors
(Circulation Research. 2009;105:827.)
© 2009 American Heart Association, Inc.


Editorial

Matrix Metalloproteinase-8 and the Regulation of Blood Pressure, Vascular Inflammation, and Atherosclerotic Lesion Growth

Ziad Mallat

From the Paris Cardiovascular Research Center, Institut National de la Santé et de la Recherche Médicale U970 and Paris-Descartes University, France.

Correspondence to Ziad Mallat, Paris Cardiovascular Research Center, Institut National de la Santé et de la Recherche Médicale U970 and Paris-Descartes University, 56, rue Leblanc, 75015 Paris, France. E-mail ziad.mallat@inserm.fr



See related articles, pages 921–929


Key Words: metalloproteinase • atherosclerosis • angiotensin • blood pressure • adhesion molecules


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

The description in the early 1990s of intriguing associations between the expression/activity of specific matrix metalloproteinases (MMPs) and signs of plaque inflammation and matrix degradation1–3 spurred an impressive effort of research to precisely define the roles of MMPs in both the development and complications of atherosclerosis. After two decades of research in this area, mechanistic studies using genetically manipulated mice with deletion or overexpression of specific MMPs, complemented with genetic epidemiological studies, have revealed more complex and, sometimes divergent, roles of MMPs in the modulation of lesion development, progression and complications.4 There are many potential explanations for these findings. Ambivalent effects of specific MMPs have been reported in different models of atherosclerosis,5 emphasizing the urgent need for clinically relevant animal models of disease complications. For example, even the use of the brachiocephalic artery of apolipoprotein (Apo)E knockout mice as a model of site-specific plaque rupture did not allow to differentiate between the roles of MMPs in plaque development versus plaque complications. A close look at this model reveals that the number of buried fibrous caps is highly proportional to lesion size, independently of mouse genetic background and MMP expression.6 The complex role of MMPs in atherosclerosis could be attributed to the diversity of biological processes relevant to this disease, which are subject to tight control by MMPs and the modulation of which could have divergent consequences for lesion development and fibrous cap stability. The MMP-controlled processes include those classically related to matrix remodeling, vascular smooth muscle cell migration and proliferation, . . . [Full Text of this Article]